Trial Profile
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Anal cancer; Colon cancer; Gallbladder cancer; Hodgkin's disease; Kaposi's sarcoma; Lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 14 Nov 2023 Results (n=36)published in the Cancer
- 30 Jul 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2024.
- 02 Mar 2021 Results (n=44) of sub-study published in the Clinical Infectious Diseases